{
    "nct_id": "NCT04419532",
    "official_title": "A Phase 1, First In Human Study of DS-1055a in Subjects With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Has a histopathologically documented locally advanced or metastatic head and neck, gastric, esophageal cancer, non-small cell lung cancer, or melanoma. Participants with other types of solid tumors may be eligible following discussion with the Sponsor.\n* Has a relapsed or refractory disease that is not amenable to curative standard therapy.\n* Is 18 years of age or older.\n* Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1, with no deterioration for two weeks.\n* Has a measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Has adequate organ function within 7 days before enrollment.\n* Is able to provide written informed consent and is willing and able to comply with the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a concurrently active second malignancy, other than adequately treated non-melanoma skin cancers, in situ melanoma or in situ cervical cancer. Participants with history of the second malignancy have been disease-free for <3 years.\n* Has a history of (non-infectious) interstitial lung disease (ILD) that required steroids, currently has ILD, or when suspected ILD cannot be ruled out by imaging at screening.\n* Has a history of severe pulmonary compromise or requirement of supplemental oxygen within 6 months before enrollment.\n* Has active hepatitis B or hepatitis C virus infection.\n* Has received prior immunotherapy with a Grade 3 or higher, or any unresolved â‰¥Grade 2 immune-related adverse event.",
    "miscellaneous_criteria": ""
}